Program
tesamorelin
Also written as “Tesamorelin” and “TH9507”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · HIV-Associated Lipodystrophy Syndrome · Pulmonary Disease, Chronic Obstructive · Diabetic Retinopathy · HIV Infections, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Theratechnologies | 60 open or running | phase 4since May 2, 2012 | Jul 20, 2005 | none ahead |
| Hudson Biotech | 11 open or running | phase 2since Mar 8, 2026 | Mar 8, 2026 | Feb 14, 2027phase 2 · NCT07481734 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 20, 2005First study: phase 3 study in HIV InfectionsNew to TheratechnologiesTheratechnologies · NCT00123253 · 412 enrolled · United States, Canada
- Jan 23, 2008Phase 3 study in LipodystrophyTheratechnologies · NCT00608023 · 263 enrolled · United States, Belgium, Canada and more
- Dec 17, 2010Phase 2 study in Diabetes Mellitus, Type 2Theratechnologies · NCT01264497 · 55 enrolled
- Jul 5, 2011Phase 2 study in Pulmonary Disease, Chronic ObstructiveTheratechnologies · NCT01388920 · 3 enrolled
- May 2, 2012Phase 4 study in Diabetic RetinopathyTheratechnologies · NCT01591902 · 129 enrolled · United States
- Nov 26, 2013Phase 1 study in HIVTheratechnologies · NCT02012556 · 18 enrolled · Canada
- Mar 8, 2026Hudson Biotech's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Hudson BiotechHudson Biotech · NCT07481734 · 120 planned · China
Ahead
- Feb 14, 2027Primary completion: phase 2 study in Non-alcoholic Fatty Liver DiseaseHudson Biotech · NCT07481734
TargetBeta
“Growth hormone-releasing hormone receptor agonist”ChEMBL 37, by rule
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07481734Non-alcoholic Fatty Liver Disease · China | 2 | Recruiting | Hudson Biotech | Feb 14, 2027 | 120 |
| NCT02012556HIV · Canada | 1 | Completed | Theratechnologies | Jul 2008 | 18 |
| NCT01591902Diabetic Retinopathy · United States | 4 | Terminated | Theratechnologies | May 2018 | 129 |
| NCT01388920Pulmonary Disease, Chronic Obstructive | 2 | Terminated | Theratechnologies | Dec 2011 | 3 |
| NCT01264497Diabetes Mellitus, Type 2 | 2 | Completed | Theratechnologies | Nov 2002 | 55 |
| NCT00608023Lipodystrophy · United States, Belgium, Canada and more | 3 | Completed | Theratechnologies | Oct 2008 | 263 |
| NCT00123253HIV Infections · United States, Canada | 3 | Completed | Theratechnologies | Nov 2006 | 412 |
How it is read
Names in the registry
- “Tesamorelin”, 5 entries
- “TH9507”, 2 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 1 study
- HIV-Associated Lipodystrophy Syndrome, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
- Diabetic Retinopathy, 1 study
- HIV Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.